PROCYSS, NCT04963920: A RCT to Assess the Performance of CytoSorb for Shock Reversal in Patients With Vasoplegic Septic Shock |
|
|
| Recruiting | N/A | 260 | Europe | Cytosorb® 300 ml | CytoSorbents Europe GmbH, BRAHMS GmbH, MedInnovation GmbH | Septic Shock | 02/25 | 05/25 | | |
| Recruiting | N/A | 3000 | Europe | CytoSorb | CytoSorbents, Inc | Septic Shock, Acute Respiratory Distress Syndrome, Trauma, Rhabdomyolysis, Cardiogenic Shock, Pancreatitis, Acute on Chronic Liver Failure, Acute Liver Failure, Burns, Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Cytokine Release Syndrome (CRS), Extracorporeal Life Support, Postoperative Endocarditis, Hemophagocytic Lymphohistiocytoses, Liver Transplant; Complications, Infectious Disease, Postoperative Vasoplegic Syndrome, Drug Overdose, Sepsis | 06/32 | 09/32 | | |
